TMCnet News
TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinforced Biologic Augmented Repair) TechniqueMALVERN, Pa., Sept. 13, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced details of the clinical research presented last week at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting in Las Vegas, Nevada. Two poster presentations revealed new data, while a third video presentation demonstrated a novel surgical technique that leverages the unique properties of OviTex® Reinforced Tissue Matrix. Robotic Assisted ReBAR of 111 Inguinal Hernias, presented by Dr. Cory Banaschak, DO and Dr. Paul Szotek, MD, MBA, FACS, Medical Director of the Indiana Hernia Center, revealed a 2.7% recurrence rate, a 1.8% surgical site occurrence rate, and no infections in patients with at least one year of follow-up. The authors concluded that robotic transabdominal preperitoneal (rTAPP) inguinal hernia repair with OviTex presents a viable and more natural repair alternative in minimally invasive surgery, an approach typically reserved for permanent synthetic meshes. Dr. Szotek stated, "The Reinforced Biologic Augmented Repair, or the ReBAR technique, applies sound hernia surgery principles while leveraging the benefits of a reinforced biologic material with a low synthetic foreign body burden. Our initial goals in adopting OviTex were to lower recurrences while decreasing the amount of synthetic foreign body implanted. That's what patients are increasingly looking for, and it makes a lot of clinical sense if you can achieve it. With over five years of experience utilizing the ReBAR technique with OviTex, it appears that we are on the way to achieving these goals." Additional data on hernia repairs performed by Drs. Szotek and Banaschak employing the ReBAR technique was recently highlighted in an article entitled, Minimizing Retained Foreign Body in Hernia Repair Using a Novel Technique: Reinforced Biologic Augmented Repair (ReBAR) published in the Journal of Clinical and Medical Research. In this prospective study of 619 implants using the ReBAR technique for a variety of open and minimally invasive inguinal and abdominal hernia repairs the authors reported an overall recurrence rate of 1.3%. Use of Ovine Reinforced Tissue Matrix in Bridged Incisional Hernia Repair, presented by Dr. DeNoto III, MD, FACS, Director of General Surgery at St. Francis Hospital in New York, analyzed recurrence rates in the treatment of abdominal hernias that require reinforcement in the absence of a primary repair. "These are some of the most complex and challenging atients to reduce the potential of a future hernia recurrence," said Dr. DeNoto. In this series, patients with bridged repairs using OviTex had a 14% recurrence rate. "To put the results of our study in perspective, at similar time points we have seen recurrence rates more than double when repaired with human or porcine mesh products. This is a major reason why patients presenting with bridged repairs are so difficult to treat and why an effective reinforcement option is much needed." For more information on the SAGES poster presentations, visit https://epostersonline.com/sages2021/ About TELA Bio, Inc. About OviTex The statements made or results achieved by TELA Bio customers described herein were achieved in their specific setting. Due to variations in clinical experience and technique, there is no guarantee that these results are typical. A surgeon must use his or her own clinical judgment when deciding which products are appropriate for treatment of a particular patient. Always refer to the package insert, product label, and/or instructions for use before using any TELA Bio product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Caution Regarding Forward-Looking Statements Investor Contact Media Contact |